Amoxicillin dosing and pharmacokinetics in obesity for the treatment of bacterial respiratory infection secondary to COVID-19: a systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v11i14.36040

Keywords:

Amoxicillin; Obesity; Pharmacokinetics; Dosage; Child.

Abstract

Objective: To conduct a systematic review of Amoxicillin (AMX) dosing and pharmacokinetics (PK) in obese subjects for the treatment of the outpatient respiratory tract infection which may be a secondary co-infection with COVID-19. Methodology: A systematic review was performed up to January 2022 on MEDLINE, EMBASE, and Web of Science. Full-text manuscripts describing AMX dosing for respiratory infection or PK in obese children, adults, and RYGB bariatric patients treated with AMX were included. Results: A total of 179 records were screened, of which 8 met the inclusion criteria. Four studies described AMX dosing in obese children and adults, while 4 described PK in obese adults and RYGB bariatric subjects. Overall, in the dosing studies, 54% of children >20 kg and 10% <40 kg with respiratory infection were considered underdosed, according to guidelines or recommendations. Underdosing of 10% occurred in both overweight and non-obese children’s groups. For morbidly obese adults, 70% were considered underdosed. In the PK studies, obese and bariatric adult subjects showed reduced exposure compared to normal weight patients for all AMX formulations. Conclusion: More PK studies are needed to confirm the optimal dose of AMX for obese patients, particularly in children. However, considering that all obese and bariatric adults had reduced exposure compared to subjects of normal weight, 1 g 8/8h should be recommended and liquid formulations are preferable for bariatric patients. To minimize the risks of therapeutic failure and avoid toxicity, a higher threshold of doses should be prescribed for obese children.

References

Alobaid, A. S., Hites, M., Lipman, J., Taccone, F. S., & Roberts J. A. (2016). Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. Int J Antimicrob Agents, 47(4):259-68. https://doi.org/10.1016/j.ijantimicag.2016.01.009

Amoxil. (2006). Label. AM:L29. Prescribing information. NDA 50-542/S-024; NDA 50-754/S-011; NDA 50-760/S-010; NDA 50-761/S-010. GlaxoSmithKline. Retrieved November 9, 2020, from https://www.accessdata.fda.gov

Amoxil. (2019). Label. GlaxoSmithKline Brazil LTDA. Retrieved March 2, 2021, from https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=amoxil

Anderson, B. J., & Holford, N. H. (2017). Getting the dose right for obese children. Arch Dis Child, 102(1):54-55. http://dx.doi.org/10.1136/archdischild-2016-311696

Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 399(10325):629-655. https://doi.org/10.1016/S0140-6736(21)02724-0

Bielicki, J. A., Barker, C. I., Saxena, S., Wong, I. C., Long, P. F., & Sharland, M. (2015). Not too little, not too much: problems of selecting oral antibiotic dose for children. BMJ, 351:h5447. https://doi.org/10.1136/bmj.h5447

Buehrle, D. J., Nguyen, M. H., Wagener, M. M., & Clancy, C. J. (2020). Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. Open Forum Infect Dis, 7(12):ofaa575. https://doi.org/10.1093/ofid/ofaa575

Caci, G., Albini, A., Malerba, M., Noonan, D. M., Pochetti, P., & Polosa, R. (2020). COVID-19 and Obesity: Dangerous Liaisons. J Clin Med, 9(8):2511. https://doi.org/10.3390/jcm9082511

Centers for Disease Control and Prevention. (2020). Defining Adult Overweight and Obesity. Division of Nutrition, Physical Activity, and Obesity. National Center for Chronic Disease Prevention and Health Promotion. Retrieved November 25, 2020, from https://www.cdc.gov/obesity/adult/defining.html

Christian-Kopp, S., Sinha, M., Rosenberg, D. I., Eisenhart, A. W., & McDonald, F. W. (2010). Antibiotic dosing for acute otitis media in children: a weighty issue. Pediatr Emerg Care, 26(1):19-25. https://doi.org/ 10.1097/PEC.0b013e3181cbeb00

Davis, J. A., & Saunders, R. (2020). Impact of weight trajectory after bariatric surgery on co-morbidity evolution and burden. BMC Health Serv Res, 20(1):278. https://doi.org/10.1186/s12913-020-5042-9

De Lorenzo, A., Romano, L., Di Renzo, L., Di Lorenzo, N., Cenname, G., & Gualtieri, P. (2020). Obesity: A preventable, treatable, but relapsing disease. Nutrition, 71:110615. https://doi.org/10.1016/j.nut.2019.110615

IBM Micromedex Drug Ref©. (2018). Copyright IBM Corporation. Application version 3.0b856

Jacobs, M. R. (2003). How can we predict bacterial eradication? Int J Infect Dis, 7:S13-S20. https://doi.org/10.1016/S1201-9712(03)90066-X

Khan, S., Hasan, S. S., Bond, S. E., Conway, B. R., & Aldeyab, M. A. (2021). Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Anti Infect Ther, 20(5):749-772. https://doi.org/10.1080/14787210.2022.2011719

Krekels, E. H. J., & Knibbe, C. A. J. (2020). Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories. Handb Exp Pharmacol, 261:231-255. https://doi.org/10.1007/164_2019_250

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100

Longo, C., Bartlett, G., Macgibbon, B., Mayo, N., Rosenberg, E., Nadeau, L., & Daskalopoulou, S. S. (2013). The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf, 22(9):970-6. https://doi.org/10.1002/pds.3461

Mellon, G., Hammas, K., Burdet, C., Duval, X., Carette, C., El-Helali, N., Massias, L., Mentré, F., Czernichow, S., & Crémieux, A. C. (2020). Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. J Antimicrob Chemother, 75(12):3611-3618. https://doi.org/10.1093/jac/dkaa368

Miller, J. L., Johnson, P. N., Harrison, D. L., & Hagemann, T. M. (2010). Evaluation of inpatient admissions and potential antimicrobial and analgesic dosing errors in overweight children. Ann Pharmacother, 44(1):35-42. https://doi.org/10.1345/aph.1M371

Montanha, M. C., Dos Santos Magon, T. F., de Souza Alcantara, C., Simões, C. F., Silva, S. R. B., Kuroda, C. M., Yamada, S. S., de Oliveira, L. E. S., Nasser, D., Junior, N. N., Mazucheli, J., Diniz, A., Paixão, P. J. P. A., & Kimura, E. (2019). Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux-en-Y gastric bypass bariatric subjects. Br J Clin Pharmacol, 85(9):2118-2125. https://doi.org/10.1111/bcp.14023

National Institute for Health and Care Excellence. (2020). British National Formulary for Children (BNFc). Retrieved January 29, 2021, from https://www.nice.org.uk

Oboza, P., Ogarek, N., Olszanecka-Glinianowicz, M., & Kocelak, P. (2022). COVID-19 and obesity: the confrontation of two pandemics. Eur Rev Med Pharmacol Sci, 26(2):695-709. https://doi.org/ 10.26355/eurrev_202201_27896

Pai, M. P. (2012). Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacother, 32(9):856-68. https://doi.org/10.1002/j.1875-9114.2012.01108.x

Rann, O., Sharland, M., Long, P., Wong, I. C. K., Laverty, A. A., Bottle, A., Barker, C. I., Bielicki, J., & Saxena, S. (2017). Did the accuracy of oral amoxicillin dosing of children improve after British National Formulary dose revisions in 2014? National cross-sectional survey in England. BMJ Open, 7(9):e016363. http://dx.doi.org/10.1136/bmjopen-2017-016363

Rocha, M. B. S., De Nucci, G., Lemos, F. N., de Albuquerque Lima Babadopulos, R. F., Rohleder, A. V. P., Fechine, F. V., Antunes, N. J., Mendes, G. D., do Nascimento, D. F., de Moraes, M. O., & de Moraes, M. E. A. (2019). Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin. Obes Surg, 29(3):917-927. https://doi.org/10.1007/s11695-018-3591-3

Sampson, M., Cohen-Wolkowiez, M., Benjamin, D. Jr., Capparelli, E., & Watt, K. (2013). Pharmacokinetics of Antimicrobials in Obese Children. GaBI J, 2(2):76-81. https://doi.org/10.5639/gabij.2013.0202.025

Seaton, R. A., Cooper, L., Gibbons, C. L., Malcolm, W., Choo-Kang, B., Griffith, D., Dundas, S., Brittain, S., Hamilton, K., Jeffreys, D., McKinney, R., Guthrie, D., & Sneddon, J. (2021). Antibiotic prescribing for respiratory tract infection in patients with suspected and proven COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals. JAC Antimicrob Resist, 3(2):dlab078. https://doi.org/10.1093/jacamr/dlab078

Serra Soler, G., Galán Ramos, N., Martínez-López, I., Delgado Sánchez, O., & Quevedo Juanals, J. (2009). Study of drug dose calculation for morbidly obese patients. Farm Hosp, 33(6):330-4. https://doi.org/10.1016/S1130-6343(09)72976-9

Smit, C., De Hoogd, S., Brüggemann, R. J. M., & Knibbe, C. A. J. (2018). Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol, 14(3):275-285. https://doi.org/10.1080/17425255.2018.1440287

Soares, A. L. P. P. D. P., Montanha, M. C., Alcantara, C. D. S., Silva, S. R. B., Kuroda, C. M., Yamada, S. S., Nicacio, A. E., Maldaner, L., Visentainer, J. V., Simões, C. F., Locatelli, J. C., Lopes, W. A., Mazucheli, J., Diniz, A., Paixão, P. J. P. A., & Kimura, E. (2021). Pharmacokinetics of amoxicillin in obese and non-obese subjects. Br J Clin Pharmacol, 87(8):3227-3233. https://doi.org/10.1111/bcp.14739

Tchang, B. G., Saunders, K. H., & Igel, L. I. (2021). Best Practices in the Management of Overweight and Obesity. Med Clin North Am, 105(1):149-174. https://doi.org/10.1016/j.mcna.2020.08.018

Thambavita, D., Galappatthy, P., Mannapperuma, U., Jayakody, L., Cristofoletti, R., Abrahamsson, B., Groot, D. W., Langguth, P., Mehta, M., Parr, A., Polli, J. E., Shah, V. P., & Dressman, J. (2017). Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate. J Pharm Sci, 106(10):2930-2945. https://doi.org/10.1016/j.xphs.2017.04.068

The jamovi project. (2021). jamovi (Version 1.6) [Computer Software]. Retrieved May 28, 2021, from https://www.jamovi.org

Vasheghani, M., Hessami, Z., Rekabi, M., Abedini, A., & Qanavati, A. (2022). Evaluating Possible Mechanisms Linking Obesity to COVID-19: a Narrative Review. Obes Surg, 32(5):1689-1700. https://doi.org/10.1007/s11695-022-05933-0

World Health Organization. (2021a). Obesity and overweight. Newsroom. Retrieved February 17, 2022, from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

World Health Organization. (2021b). Pneumonia. Newsroom. Retrieved February 17, 2022, from https://www.who.int/news-room/fact-sheets/detail/pneumonia

Wu, C. P., Adhi, F., & Highland, K. (2020). Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19. Cleve Clin J Med, 2;87(11):659-663. https://doi.org/10.3949/ccjm.87a.ccc015

Xing, J., & Chen, J. D. (2004). Alterations of gastrointestinal motility in obesity. Obes Res, 12(11):1723-32. https://doi.org/10.1038/oby.2004.213

Downloads

Published

21/10/2022

How to Cite

DALLA ROSA, G. M. de L. L.; SILVA, S. R. B.; YAMADA, S. S.; PAIXÃO, P. J. P. A.; MONTANHA, M. C.; KIMURA, E. Amoxicillin dosing and pharmacokinetics in obesity for the treatment of bacterial respiratory infection secondary to COVID-19: a systematic review. Research, Society and Development, [S. l.], v. 11, n. 14, p. e130111436040, 2022. DOI: 10.33448/rsd-v11i14.36040. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/36040. Acesso em: 8 dec. 2022.

Issue

Section

Review Article